載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$0.8398
+US$0.0048 · +0.57%
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
前收盤價
US$0.8398
+US$0.0048 · +0.57%
盤中時間採用ET。市場資料可能有所延遲。
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
日內區間
目前US$0.8398
52週區間
目前US$0.8398
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
41
合理估值
情緒
44
多空交錯
風險
97
極高風險
動能
19
強勢下行
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
日內區間
目前US$0.8398
52週區間
目前US$0.8398
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 |
|---|---|---|---|---|
| 研究與開發 | 641.83萬 USD | 492.5萬 USD | 424.05萬 USD | 685.57萬 USD |
| 銷售、一般及管理費用 | 1710.44萬 USD | 1564.77萬 USD | 788.08萬 USD | 285.75萬 USD |
| 營業費用 | 2352.28萬 USD | 2057.27萬 USD | 1212.12萬 USD | 971.32萬 USD |
| 利息收入 | 3.64萬 USD | — | — | — |
| 利息支出 | 21.8萬 USD | — | — | — |
| 折舊和攤銷 | — | — | — | 971.32萬 USD |
| 營業利益 | −2352.28萬 USD | −2057.27萬 USD | −1212.12萬 USD | −971.32萬 USD |
| 淨利 | −2476.14萬 USD | −2114.87萬 USD | −1269.72萬 USD | −1086.52萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 614.46%報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
